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❙ABSTRACT❙
Since the first descriptions of their active functions more than ten years ago, small non-coding RNA species termed 
microRNA (miRNA) have emerged as essential regulators in a broad range of adaptive and maladaptive cellular processes. 
With an exceptionally rapid pace of discovery in this field, the dysregulation of many individual miRNAs has been 
implicated in the development and progression of various cardiovascular diseases. MiRNA are also expected to play crucial 
regulatory roles in the progression of pulmonary vascular diseases such as pulmonary hypertension (PH), yet direct insights 
in this field are only just emerging. This review will provide an overview of pulmonary hypertension and its molecular 
mechanisms, tailored for both basic scientists studying pulmonary vascular biology and physicians who manage PH in their 
clinical practice. We will describe the pathobiology of pulmonary hypertension and mechanisms of action of miRNA 
relevant to this disease. Moreover, we will summarize the potential roles of miRNA as biomarkers and therapeutic targets as 
well as future strategies for defining the cooperative actions of these powerful effectors in pulmonary vascular disease.
(J Korean Soc Hypertens 2013;19(1):1-16)
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Introduction
The most well-studied sequences in the human genome 
are those of protein-coding genes, with the coding exons 
of these genes comprising approximately 1.5% to 2% of 
the genome.1) Recently, epigenetic alterations of the ge-
nome (e.g., DNA methylation) and the transcriptome 
(e.g., repression by non-coding RNA) have been recog-
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nized as powerful and alternative gene regulatory mecha-
nisms, and it has become apparent that the non-pro-
tein-coding portion of the genome plays a significant role 
in normal development and pathophysiology of human 
disease.2) In particular, microRNA (miRNA) are small, 
evolutionarily conserved, non-protein coding RNA mole-
cules that have been found to carry especially pleiotropic 
and ubiquitous actions in gene regulation and human 
pathogenesis.
At present, greater than 1,400 distinct miRNA species 
have been identified or predicted in human cells.3) 
Moreover, roughly 50% and 60% of all mammalian mes-
senger RNA (mRNA) transcripts are estimated to be di-
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Fig. 1. MicroRNA (miRNA) biogenesis and mechanism of action. MiRNAs undergo several nuclear and cytosolic processing 
steps before maturation to a biologically active form (19-24 nt). After processing, the mature miRNA is incorporated into the 
RNA󰠂induced silencing complex (RISC). Through binding to the complementary sites in the 3’ untranslated region of their target
genes, miRNA promote down󰠂regulation of the protein synthesis via translational repression or messenger RNA (mRNA) 
degradation.
rect targets of such miRNA.4,5) MiRNAs are genomically 
encoded either as single genes (“intergenic”), as a poly-
cistronic family, or as a gene embedded in an intron of 
a protein-coding gene (“intronic”). Upon transcription to 
an approximately 1,000 nucleotide precursor (primary 
miRNA or pri-miRNA), several nuclear and cytosolic 
processing steps occur leading to maturation to a mature, 
biologically active double stranded miRNA duplex, con-
sisting of a prototypical active strand that binds target 
transcripts for gene repression and an “inactive” strand 
(Fig. 1). The mature miRNA is incorporated into the 
RNA-induced silencing complex including the RNA-bind-
ing protein Argonaute 2 which is instrumental in media-
ting the recognition and binding of mature miRNA with 
its target mRNA transcript(s).6) At the 5’ end of each 
miRNA strand exists a “seed sequence” (at positions 2-8) 
which is an important determinant for complementary 
strand target sequence binding, typically at the 3’ un-
translated region (3’UTR) of the target mRNA transcript. 
The remainder of the miRNA sequence typically binds 
imperfectly, creating bulges and mismatches in the 
miRNA:mRNA heteroduplex.7,8) Therefore, a single 
miRNA sequence can target hundreds of mRNAs by low 
miRNA-target complementarity.9) Furthermore, more than 
one miRNA can cooperatively bind to the same 3’UTR 
and, thus, affect a stronger action.10) As a result of such 
binding, a miRNA can promote the specific down-regu-
lation of a cadre of mRNA targets, through translational 
Degradation
degradation
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repression and/or mRNA degradation.11,12)
In experiments involving both cultured cardiovascular cell 
types and rodent models of cardiovascular disease, specific 
gain- and loss-of-function studies of individual miRNA 
have elucidated their distinct roles in cardiovascular devel-
opment and physiological function. Overall, miRNA tend 
to act by “fine tuning” the regulation of gene expression, dis-
ruption of which can have dramatic phenotypic consequences 
especially under stressful conditions.13) Accordingly, multiple 
miRNA have been implicated in cardiomyocyte biology 
such as those involved in myocardial fibrosis, infarction, 
and hypertrophy (Fig. 2A).14,15) Several miRNA have also 
been identified as modulators of systemic vascular re-
modeling, such as atherosclerosis, vasomotor tone and 
hypertension, and neointimal formation (Fig. 2B).16,17) 
However, the importance of miRNA in the pulmonary 
vasculature is just becoming defined. Here, we aim to re-
view our basic understanding of the molecular mecha-
nisms important in pulmonary vascular diseases such as 
pulmonary hypertension with the intent to correlate the 
biology of miRNA with these processes. Consequently, 
we hope to emphasize the clinical importance of studying 
miRNA in this context, providing a platform for discov-
ering new molecular mechanisms of pulmonary vascular 
disease, identifying novel miRNA biomarkers of disease, 
and potentially determining putative miRNA-based ther-
apeutic targets to ameliorate, regress, or prevent pulmo-
nary hypertension.
Pulmonary hypertension and its known 
molecular pathogenic mechanisms
1. Clinical definition & classification of 
pulmonary hypertension
Pulmonary hypertension (PH) is a hemodynamic state 
in which the pulmonary artery pressure is abnormally 
high and is clinically defined as a resting mean pulmo-
nary arterial pressure (mPAP) > 25 mm Hg.18) PH is a 
progressive disease of various etiologies that has a poor 
prognosis, ultimately leading to right ventricular fail-
ure,19) multi-organ dysfunction, and often death. Based on 
the latest World Health Organization classification,20) PH 
is classified into 5 categories based on presumed primary 
etiology: 1) pulmonary arterial hypertension (PAH), 2) 
PH owing to left heart disease, 3) PH owing to lung dis-
ease and/or hypoxia, 4) chronic thromboembolic PH, and 
5) PH with unclear, multifactorial mechanisms.
Specifically, PAH (group 1) and hypoxia-induced PH 
(group 3) have historically been the focus of substantial 
study since the first standardized classification of PH was 
released. Consequently, most of our mechanistic insights 
into PH have originated from study of these groups. 
Specifically, PAH is defined as a resting mPAP > 25 mm 
Hg or exercise-induced mPAP > 35 mm Hg, accom-
panied by an elevated pulmonary vascular resistance (>3 
Wood units), normal pulmonary capillary wedge pressure 
(<15 mm Hg), and absence of predisposing conditions 
such as left heart disease, hypoxic lung disease, and 
thromboembolic disease.20) Currently, it comprises idio-
pathic PAH (IPAH) as well as secondary PAH derived 
from genetic or familial predisposition, drug- and tox-
in-induced PAH, flow-induced PAH associated with con-
genital heart disease and cardiac shunts, persistent PH of 
the newborn, pulmonary veno-occlusive disease, and pul-
monary capillary hemangiomatosis.20) On the other hand, 
hypoxia-induced PH is defined as a resting mPAP > 25 
mm Hg accompanied by secondary diseases indicative of 
chronic hypoxic exposure, including chronic obstructive 
pulmonary disease, idiopathic pulmonary fibrosis, ob-
structive sleep apnea, and chronic high-altitude exposure. 
Despite some differences among these variants of PH, 
substantial overlap is also present at the molecular level, 
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Fig. 2. Role of microRNAs (miRNAs) in cardiovascular disease. (A) Control of cardiomyocyte function by miRNA. The pathogenic
events influencing cardiomyocytes in ischemic and hypertrophic diseases are closely controlled by multiple miRNA which regulate
cell survival, apoptosis, angiogenesis, fibrosis, and remodeling.14) (B) Control of vascular function by miRNA. Pathophenotypes
in diseased vasculature are closely controlled by miRNA, which regulate vascular integrity and remodeling.15,16) From White K, 
et al. Pulm Circ. 2012;2:278-90, with permission of Pulmonary Circulation.17)
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Fig. 3. Pathobiology of pulmonary hypertension. Multiple vascular cell types in the pulmonary arterial wall and pulmonary arterial 
circulation are involved in the pathobiology of pulmonary arterial hypertension (PAH). Vascular pathology in PAH is triggered 
by various genetic and environmental stimuli, and initial injury to the endothelium and/or adventitial fibroblasts may activate
pathogenic signaling pathways. These result in an imbalance of secreted vascular effectors that cause excessive pulmonary
vasoconstriction and abnormal vascular remodeling processes. Common histological features in PAH include intimal hyperplasia, 
medial hypertrophy, adventitial proliferation/fibrosis, occlusion of small arteries, thrombosis in situ, and infiltration of inflammatory
cells (green arrow) or progenitor cells (purple arrow). Transdifferentiation of endothelial cells or fibroblasts to vascular smooth
muscle cells may contribute as well (blue arrow). These vascular changes lead to the formation of a layer of“neointima”(red
arrow) and, in some cases, plexiform lesions (From Chan SY, et al. J Mol Cell Cardiol. 2008;44:14-30, with permission of PubMed
Central).34)
with both disease types displaying pronounced imbalance 
of cell growth and cell death, leading to remodeling of 
the pulmonary vasculature as well as changes in vaso-
motor tone and thrombotic potential. It remains unproven 
if similar mechanisms of disease primarily contribute to 
the burden of vascular disease seen in groups 2, 4, and 
5. However, the functional importance of these sim-
ilarities in all groups has been suggested by clinical data 
demonstrating that pulmonary vasodilator therapy is ef-
fective across groups 1 to 4.21) In this review, we will fo-
cus primarily on disease mechanisms directly applicable 
to these two groups, with possible extrapolation of those 
principles to other types of PH.
2. Histopathobiology of pulmonary hypertension
In general, various forms of PH and PAH are marked by 
a complex panvasculopathy affecting small pulmonary arte-
rioles, marked by the dysregulation of multiple cell types 
and molecular pathways (Fig. 3). Our understanding of the 
underlying pathobiology of PH has become increasingly 
MicroRNA in the Diseased Pulmonary Vasculature
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complex as multiple genetic and molecular pathways have 
been identified.22) Common histologic features in PH in-
clude intimal hyperplasia, medial hypertrophy, adventitial 
proliferation/fibrosis, occlusion of small arteries, thrombo-
sis in situ, and infiltration of inflammatory/progenitor 
cells.23) Later in disease, these changes can result in dis-
ordered angiogenesis and formation of pathognomonic 
complex vascular lesions, or so-called plexiform lesions.24) 
This vascular pathology is triggered by various genetic 
and environmental stimuli, and multiple vascular cell types 
in the pulmonary artery and pulmonary arterial circulation 
contribute to the specific response to injury and the devel-
opment of PH.25) The initiating cell type remains unclear, 
but abnormalities in pulmonary endothelial cell and pul-
monary artery smooth muscle cells as well as trans-
differentiation among these two populations may primarily 
contribute to the development of PH.26) Adventitial fibro-
blasts likely contribute as well, as they display increased 
proliferative capacity in PH, further contributing to vas-
cular fibrosis. Inflammatory cells and activated platelets 
can predominate in end-stage PH, but our understanding is 
limited regarding the mechanistic role of these populations 
in disease progression. Finally, pulmonary arterial remod-
eling is associated with chronic inflammatory events and 
may promote the recruitment of circulating or resident 
progenitor cells, which in turn may dysregulate vascular 
proliferative capacity.27,28)
3. Molecular mechanisms of pulmonary 
hypertension
Inherent in the complicated phenotypes that are ob-
served as PH develops are the complex and overlapping 
molecular mechanisms that appear to be driving and/or 
are associated with these conditions. From a genetic per-
spective, mutations in the transforming growth factor-β 
(TGF-β) receptor superfamily, particularly the bone mor-
phogenetic protein receptor type 2 (BMPR2) gene29,30) 
have been genetically linked to PAH and likely play a 
causative role in the development of disease. Genetic ab-
normalities in serotonin signaling and transport have also 
been associated with PAH in human cohorts.31) Alternative 
mechanisms involving complementary “modifier” genes 
could contribute to a genetic predisposition to PH, as 
suggested for single nucleotide polymorphisms in genes 
encoding for the voltage-gated potassium channel KV1.5 
and the transient receptor potential cation channel, sub-
family C, member 6.32) In addition to genetic predis-
position, various physiologic, acquired, and/or exogenous 
stimuli modulate the development of PH. Some of these 
stimuli have been studied to a sufficient degree at the 
molecular level, while other factors carry much less de-
fined mechanisms of action (Fig. 4). Downstream of the 
genetic and acquired triggers of PH, the histopathologic 
processes that predominate later stages of disease include 
vasoconstriction, smooth muscle cell and endothelial cell 
proliferation, and thrombosis.33) Historically, it was thought 
that these processes are influenced primarily by a com-
plex and dysregulated balance of vascular effectors con-
trolling vasodilatation and vasoconstriction, growth sup-
pressors and growth factors, and pro-versus anti-throm-
botic mediators (Fig. 5). While these factors are certainly 
important in the overall disease process, it is now apparent 
that these effectors are subject to upstream, over-arching 
regulatory pathways that affect the action of multiple vas-
oactive molecules.34) These include mitochondrial and 
metabolic dysregulation, alterations in potassium channel 
signaling and intracellular calcium handling, perturbations 
in tyrosine kinase and Rho kinase signaling, inflammatory 
stimuli, and extracellular matrix disturbances, among others.
MicroRNA and pulmonary vascular disease
Considering the complexity and overlapping nature of 
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Fig. 4. Pathogenic mechanisms of pulmonary hypertension (PH). Complex, pathogenic mechanisms that connect genetic 
predisposition, acquired, and exogenous factors play a role in the downstream dysfunction/dysregulation metabolism and 
signaling pathways resulting in PH.
the molecular mechanisms important in PH along with 
the pleiotropic and ubiquitous modes of action of miRNA 
in mammalian tissue, it is reasonable to expect that 
miRNA carry substantial roles in modulating pulmonary 
vascular homeostasis and the development of pulmonary 
vascular diseases. However, unlike more expansive scien-
tific literature describing the expression and actions of 
miRNA in other cardiovascular diseases, only a handful 
of miRNA thus far has been identified as direct modu-
lators in PH. In part, this may be a reflection of the ana-
tomic inaccessibility and difficulty in obtaining relevant 
disease tissue for study, especially as the frequency of 
lung transplantation for PH has been declining over the 
past decade. Nonetheless, a more substantial number of 
studies have been published recently that have identified 
a growing list of core miRNA critical in mediating these 
pulmonary vascular disease phenotypes.
1. MicroRNA related to upstream triggers of 
pulmonary hypertension and dysregulated in 
end-stage pulmonary hypertension
To begin to identify the functions of miRNA in PH, it has 
proven useful to relate specific miRNA to this disease if they 
carry already established functions related to upstream trig-
gers of this disease. Stemming from the substantial studies of 
hypoxia-induced PH over the past two decades, the identi-
fication of hypoxia-responsive miRNA, termed as 
“hypoxamirs” by our group,35) has offered a reasonable start-
ing point. Hypoxia induces a complex set of adaptations that 
influence cellular survival and function in the pulmonary 
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Fig. 5. Roles of vascular effectors in the pathogenesis of pulmonary arterial hypertension (PAH). Vascular effectors have been
shown to have different roles in the pathogenesis of pulmonary hypertension (PH) (From Chan SY, et al. J Mol Cell Cardiol. 
2008;44:14-30, with permission of PubMed Central).34)
vasculature. In large part, these cellular adaptations are tran-
scriptionally controlled by the hypoxia-inducible factors 
(HIFs). HIF consists of an unstable α subunit and a stable β 
subunit, and three HIF-α proteins have been described in 
higher metazoans: HIF-1α, HIF-2α, and HIF-3α.36,37) Under 
hypoxia, HIF-α protein is not hydroxylated and is stabilized 
for heterodimerization with HIF-β. This heterodimer can bind 
specific sites in gene promoters termed hypoxia response ele-
ments, thereby inducing downstream transcription. HIF di-
rectly induce the transcription of more than 100 different 
genes, influencing a wide range of cellular processes. In ag-
gregate, these events effectively reprogram the hypoxic cell 
for acute survival in a low oxygen environment.38,39) Yet, 
such reprogramming is detrimental if chronically persistent. 
Consequently, HIF and its downstream targets have been im-
plicated as crucial pathogenic factors across multiple clinical 
categories of PH, even in cases of PAH which are not di-
rectly associated with exogenous hypoxic exposure.40) 
Although more than 100 hypoxamirs have been identified, 
most demonstrate modest induction, and are up-regulated on-
ly in certain cellular contexts or by HIF directly. Of these hy-
poxamirs, only a few have been defined as direct modulators 
of pulmonary vascular function and disease.
As well-established triggers of PH, inflammation and BMP 
pathway are also closely related with miRNA functions. 
Moreover, there is a considerable overlap among miRNAs in 
these categories and hypoxamirs. Although the direct actions 
of many of these miRNAs are still unknown, there is grow-
ing evidence that TGF-β and BMP superfamily signaling are 
intricately related to miRNA biology at multiple mechanistic 
levels?via regulating miRNA expression at the transcrip-
tional and post-transcriptional levels and via inducing neg-
ative regulatory feedback loops through multiple miRNA 
with predicted and increasingly validated roles in repressing 
expression of TGF/BMP signaling components. Considering 
the fact that BMPR2 haploinsufficiency represents a major 
Effect on
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in PAHVascular effector
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Fig. 6. Validated actions of microRNA (miRNA) in pulmonary hypertension (PH). MiRNA are listed that carry confirmed functions
in controlling PH in rodents and humans, as categorized by protective or pathogenic roles. Down-regulation of miR-145 protects 
against the development of pulmonary arterial hypertension (PAH), possibly through attenuation of myocardin expression.49)
MiR-328 directly represses L-type calcium channel-α1C expression, resulting in reduction of pulmonary vasoconstrictive 
properties. Down-regulation of insulin growth factor 1 receptor may also contribute to pulmonary artery smooth muscle cell 
apoptosis.50) MiR-21 down-regulates RhoB and Rho-kinase activity to protect against mechanisms driving PAH.41) An antagomir
directed against miR-20a restored functional bone morphogenetic protein receptor type 2 (BMPR2) signaling preventing PAH.48)
For miR-17, the BMPR2 transcript is a predicted and validated target in cultured vascular cells.47) MiR-204 directly targets Src 
homology 2 domain-containing tyrosine phosphatase (SHP2) expression that inhibits nuclear factor of activated T cells (NFAT)
expression playing a protective role against PAH.44) Down-regulation of miR-424 and miR-503 in PAH is associated with increased
fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor 1 (FGFR1) expression.51) KLF4, Kruppel-like factor-4; IGF-1,
insulin-like growth factor.
genetic predisposing risk factor for development of PAH in 
hereditary and familial cases, such a mechanistic connection 
may be an especially fruitful focus for research in PH. Yet, 
because of the sheer number of miRNA directly implicated 
in such TGF/BMP signaling loops, it is unlikely that a single 
miRNA alone serves as a predominant regulator of such 
signaling. Rather, we would expect that the coordinated ac-
tions of multiple related miRNA may synergize to affect a 
final pathophenotypic shift in PH. Yet, these principles re-
main to be confirmed in vivo.
Confidence that any of these miRNA may influence PH 
has been bolstered by overlap with the results of recent 
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screens that identify miRNA that are dysregulated in PH 
in vivo. On one hand, we have designed an in silico com-
putational network-based screen to rank a group of 29 
miRNA with the highest likelihood of influencing the PH 
phenotype, based on the proportion of their direct targets 
on a network of genes important in this disease.41) 
Importantly, a large proportion of these miRNA have 
been implicated previously in hypoxic, inflammatory, and 
TGF/BMP signaling. On the other hand, several 
high-throughput expression screens of miRNA dysregu-
lated in PH have been reported recently. One early study 
analyzed 350 miRNAs in whole lung homogenates de-
rived from rodent models of PH.42) Based on the level of 
dysregulation in one or multiple animal models, miR-322, 
miR-451, miR-21, miR-22, miR-30c, let-7f, and let-7a 
were further validated in both rodent and human examples 
of disease. A follow-up study subsequently reported alter-
ations in miR-21 and miR-451, accompanied by dysregu-
lation of miR-210 and miR-144.43) Yet, because they rep-
resent the net changes of a combination of pulmonary cell 
types, these results do not necessarily reflect the exact 
miRNA profiles in the specific diseased pulmonary 
vessels. A high-throughput miRNA screen method was 
utilized by Courboulin et al.44) in studying cultured ex 
vivo pulmonary arterial smooth muscle cells (PASMCs) 
obtained from patients suffering from IPAH as compared 
with healthy individuals. Of those found to be dynam-
ically altered in IPAH-derived PASMCs, specific ex-
pression profiles were confirmed in lung biopsies derived 
from IPAH patients. In total, six miRNA were found to 
be consistently up-regulated in disease, including 
miR-138, miR-367, miR-276, miR-302b, miR-145, and 
miR-450a, while miR-204 was the only miRNA exhibiting 
substantial down-regulation. Recently, Bockmeyer et al.45) 
also reported the in situ staining of specific miRNA in 
plexiform lesions in human PH lung. From the study of 
12 PH patient samples as compared with 8 healthy con-
trols, an up-regulation of miR-21 along with miR-126 was 
noted in plexiform lesions as compared with a down-regu-
lation of miR-204 and miR-143/145. Importantly, the 
mechanistic significance of a few of these miRNA has 
been characterized further, but the putative importance of 
other dysregulated miRNA remains to be defined.
2. Validated microRNA controlling pulmonary 
hypertension
Based on the above screening strategies, a handful of 
miRNA have been mechanistically validated in their roles 
controlling PH in rodents and human in vivo (Fig. 6). 
Based on the previously described high-throughput screen 
of diseased human PASMCs cultured ex vivo demonstrat-
ing a down-regulation of miR-204, miR-204 inhibition 
was found to incite a hyper-proliferative and anti-apoptotic 
cellular phenotype as well as frank PH in a rodent model 
via the miR-204-dependent regulation of SHP2, Src activ-
ity, and downstream metabolic pathways.44) Separately, 
based on the previously described network-based ap-
proach, our group confirmed that miR-21 is up-regulated 
in examples of mouse and human PH by hypoxia, in-
flammatory cytokines, and BMPR2-dependent signaling, 
thus leading to a down-regulation of its direct target 
RhoB, Rho kinase activity, and PH in vivo.41) As induced 
by the interleukin-6/signal transducer and activator of tran-
scription 3 inflammatory pathway, the miR-17-92 cluster 
can directly target BMPR2 in pulmonary vascular cell 
types.46) Furthermore, it was recently demonstrated that a 
miR-17 inhibitor improved heart and lung functions in the 
PH mouse and rat models.47) Similarly, an inhibitor of 
miR-20a reduced PH in hypoxic mice, potentially through 
a mechanism involving the rescue of BMPR2 
expression.48) More recently, the smooth muscle-specific 
miR-145 was found to induce PH in vivo presumably 
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through its down-regulation of multiple targets that influ-
ence the contractile phenotype of diseased PASMCs.49) 
Additionally, by virtue of its hypoxic induction, the hypo-
xamir miR-328 has been implicated in PH via its re-
pressive effects on L-type Ca(2+) channel genes and the 
insulin growth factor 1 receptor, subsequently driving 
PASMC apoptosis.50) Finally, it was recently reported that 
apelin deficiency drives a down-regulation of miR-424 and 
miR-503 in pulmonary arterial endothelial cells in PH, 
thus driving a de-repression of the direct targets fibroblast 
growth factor 2 and its receptor and thus affecting pulmo-
nary vascular proliferative capacity.51) Validation of further 
causative actions of miRNA in this disease is expected to 
exponentially increase over next years, especially as im-
provements in both computational modeling and in vivo 
manipulation of multiple miRNA become optimized.
Further clinical implications of microRNA biology
1. Circulating microRNA and possible roles in 
pulmonary hypertension
Beyond the canonical intracellular actions of miRNA in 
the pulmonary vasculature itself, extracellular forms of 
miRNA may also play an important role in the regulation 
of pulmonary vascular function. Recently, extracellular 
miRNA have been detected in the bloodstream and circu-
late in a remarkably stable form.52-54) Increasing evidence 
suggests that secreted miRNAs are protected from degra-
dation in several different mechanisms. These mecha-
nisms include storage of miRNAs in microparticles 
(exosomes, microvesicles, and apoptotic bodies),55,56) pro-
tein complexes (Argonaute2),57) or lipoprotein complexes 
(high-density lipoprotein).58) It has also been suggested 
that they are released passively as a by-products of dead 
cells.59) Only a handful of circulating miRNA have been 
identified in PH. For example, down-regulation of plasma 
miR-21 has been reported in blood from patients with 
idiopathic PAH.42) Furthermore, it has been demonstrated 
that plasma miR-150 levels are down-regulated, and re-
duction of circulating miR-150 correlates with poor sur-
vival in patients with PAH.60) Although their exact roles 
in PH pathogenesis are unclear, recent studies suggest 
that circulating miRNAs might play a role as mediators 
of cell-to-cell communication.58,61-63) Thus, it is possible 
that miRNA may act as unique molecular messengers in 
PH, enabling communication between the disease pulmo-
nary vasculature and other tissues. Furthermore, due to 
their remarkable stability in the circulation, miRNAs 
have been studied for their potential role as diagnostic 
and/or prognostic biomarkers in cardiovascular diseases 
including myocardial infarction, heart failure, peripheral 
artery disease, hypertension, and diabetes.64-66) Comprehen- 
sive analysis of circulating miRNA in PH has not yet 
been completed and may demonstrate potential for diag-
nostic use, but these results may vary greatly on the loca-
tion of plasma withdrawal (venous, arterial, or pulmonary 
arterial location) as a reflection of the originating tissue 
source of such circulating miRNA.
2. MicroRNA as therapeutic targets in pulmonary 
hypertension
As potent and crucial regulators in a wide variety of 
diseases, miRNAs have been also emerged as novel ther-
apeutic targets but have yet to be substantially studied in 
PH. Currently the most widely effective approach to in-
hibit miRNA in vivo is the use of antisense oligonucleo-
tide inhibitors (antagomirs or antimiRs). To increase the 
stability of miRNA inhibitors and allow their entry into 
mammalian cells without the need for additional trans-
fection reagent, further chemical modification can be 
added, such as locked nucleic acid oligonucleotides, poly-
lysine-conjugated peptide nucleic acids, and cholester-
MicroRNA in the Diseased Pulmonary Vasculature
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ol-conjugated moieties.67,68) Such inhibitors typically car-
ry the complimentary reverse sequence of the active 
strand of a specific mature miRNA. This approach re-
lieves the inhibition of the target genes by the miRNA 
and leads to the increase of expression of the target 
genes.69) The first mammalian in vivo study used an anta-
gomir to inhibit miR-122 and reported reduction of the 
level of the miRNA of interest and up-regulation of tar-
get genes.70) Studies using antagomirs against miR-133 or 
miR-21 have been demonstrated that cardiac miRNAs al-
so can be targeted with this approach.71,72) Recently, in 
rodent models of PH, hemodynamic and histologic pa-
rameters of PH have been modulated by various miRNA 
inhibitors, including miR-21,41,43) miR-17,47) miR-20a,48) 
miR-145,49) and miR-424/503.51) Alternatively, in circum-
stances when miRNAs are down-regulated in the disease 
state to induce disease, a different approach is needed for 
pathophenotypic reversal. To increase the active concen-
tration of a specific miRNA, one successful approach has 
entailed the use of synthetic RNA duplexes designed to 
mimic the native miRNA (miR mimics). In the monocrota-
line-induced PAH rat model, nebulization of miR-204 mim-
ics was reported to reduce disease severity significantly.44)
Although miRNA-based therapy continues to be the 
subject of substantial investigation in both the academic 
and biotechnology sectors, a number of challenges remain. 
Antisense technology has the potential to induce dose-de-
pendent off-target effects, especially in contexts that en-
tail high concentrations necessary for vascular delivery. 
Thus far, the ability to specifically deliver inhibitors to 
the pulmonary vasculature has yet to be realized without 
affecting other tissues. The advent of nanoparticle-based 
therapeutics may further advance the applicability of 
miRNA inhibition in PH. Biodegradable polymer nano-
particles represent a means to effectively deliver miRNA 
inhibitors, while minimizing the drawbacks of chemical 
modification that include systemic sequestration in the 
liver70) and much higher doses required to achieve 
efficacy.73,74) Furthermore, by utilizing a technique similar 
to Cheng et al.,75) it may be possible to engineer nano-
particles carrying miRNA inhibitors with cell-penetrating 
peptides that may specifically target absorption across the 
airway and into the pulmonary vasculature. Finally, due 
to recent appreciation that a single miRNA may target 
many genes or pathways and multiple miRNAs may af-
fect the same target, miR-based therapeutics may encoun-
ter substantial difficulty in tailoring a specific effect on 
a single target to influence disease phenotype in vivo. 
More effective miRNA-based strategies may necessitate 
the therapeutic targeting of multiple miRNA that work 
via the same network of targets to enforce a particular 
pathophenotype. Yet, challenges still remain even to 
identify rigorously the networks of those miRNA and 
their targets that carry the most robust actions in the con-
trol of PH in vivo.
Conclusion
In summary, as more miRNA targets are identified, we 
anticipate a substantial increase in our understanding of the 
molecular actions of various miRNA in PH. Given their 
pleiotropic actions in modulating multiple gene targets, we 
suspect that many of these may even serve as central mo-
lecular “lynchpins” connecting diverse upstream disease 
triggers to a common pathologic pulmonary vascular result. 
We predict rapid advances in this nascent field of study, 
including improved methods to integrate network and sys-
tems biology with evolving technologies in cell culture and 
in vivo experimentation with miRNA. As a result, our dis-
covery process will be further accelerated in order to iden-
tify more comprehensively all relevant miRNA important 
in this highly morbid condition, with the ultimate goal of 
rapidly translating these insights and technology to possible 
regression, reversal, or prevention of PH.
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J Korean Soc Hypertens 2013;19(1):1-16  13
Conflict of interest
No potential conflict of interest relevant to this article 
was reported.
Acknowledgements
We thank S. Tribuna for expert administrative assistance. 
This work was supported by the National Institutes of 
Health (KO8 grant), the Lerner, Harris, Radovsky-McArthur, 
and Watkins Funds, Gilead Research Scholars Fund, and 
the Pulmonary Hypertension Association (S.Y.C.).
References
1. Alexander RP, Fang G, Rozowsky J, Snyder M, Gerstein MB. 
Annotating non-coding regions of the genome. Nat Rev 
Genet. 2010;11:559-71.
2. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: 
insights into functions. Nat Rev Genet. 2009;10:155-9.
3. Esteller M. Non-coding RNAs in human disease. Nat Rev 
Genet. 2011;12:861-74.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, of-
ten flanked by adenosines, indicates that thousands of human 
genes are microRNA targets. Cell. 2005;120:15-20.
5. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mamma-
lian mRNAs are conserved targets of microRNAs. Genome 
Res. 2009;19:92-105.
6. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, 
Hannon GJ. Argonaute2, a link between genetic and bio-
chemical analyses of RNAi. Science. 2001;293:1146-50.
7. Bartel DP. MicroRNAs: target recognition and regulatory 
functions. Cell. 2009;136:215-33.
8. Brodersen P, Voinnet O. Revisiting the principles of 
microRNA target recognition and mode of action. Nat Rev 
Mol Cell Biol. 2009;10:141-8.
9. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge 
CB. Prediction of mammalian microRNA targets. Cell. 
2003;115:787-98.
10. Doench JG, Petersen CP, Sharp PA. siRNAs can function as 
miRNAs. Genes Dev. 2003;17:438-42.
11. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms 
of post-transcriptional regulation by microRNAs: are the an-
swers in sight? Nat Rev Genet. 2008;9:102-14.
12. Carthew RW, Sontheimer EJ. Origins and mechanisms of 
miRNAs and siRNAs. Cell. 2009;136:642-55.
13. Liu N, Olson EN. MicroRNA regulatory networks in car-
diovascular development. Dev Cell. 2010;18:510-25.
14. Small EM, Olson EN. Pervasive roles of microRNAs in car-
diovascular biology. Nature. 2011;469:336-42.
15. Abdellatif M. Differential expression of microRNAs in dif-
ferent disease states. Circ Res. 2012;110:638-50.
16. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs 
in vascular diseases, inflammation, and angiogenesis. 
Cardiovasc Res. 2008;79:581-8.
17. White K, Loscalzo J, Chan SY. Holding our breath: the 
emerging and anticipated roles of microRNA in pulmonary 
hypertension. Pulm Circ. 2012;2:278-90.
18. McLaughlin VV, Davis M, Cornwell W. Pulmonary arterial 
hypertension. Curr Probl Cardiol. 2011;36:461-517.
19. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. 
Mechanisms of disease: pulmonary arterial hypertension. Nat 
Rev Cardiol. 2011;8:443-55.
20. Simonneau G, Robbins IM, Beghetti M, Channick RN, 
Delcroix M, Denton CP, et al. Updated clinical classification 
of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 
Suppl):S43-54.
21. Lourenco AP, Fontoura D, Henriques-Coelho T, Leite-Moreira 
AF. Current pathophysiological concepts and management of 
pulmonary hypertension. Int J Cardiol. 2012;155:350-61.
22. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, 
MacLean MR, et al. Cellular and molecular basis of pulmo-
nary arterial hypertension. J Am Coll Cardiol. 2009;54(1 
Suppl):S20-31.
23. Archer SL, Weir EK, Wilkins MR. Basic science of pulmo-
nary arterial hypertension for clinicians: new concepts and 
experimental therapies. Circulation. 2010;121:2045-66.
24. Tuder RM. Pathology of pulmonary arterial hypertension. 
Semin Respir Crit Care Med. 2009;30:376-85.
25. Jeffery TK, Morrell NW. Molecular and cellular basis of pul-
monary vascular remodeling in pulmonary hypertension. 
Prog Cardiovasc Dis. 2002;45:173-202.
26. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction 
in pulmonary hypertension. Circulation. 2004;109:159-65.
27. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, 
MicroRNA in the Diseased Pulmonary Vasculature
14  The Korean Society of Hypertension
Reeves JT, et al. Hypoxia-induced pulmonary vascular re-
modeling requires recruitment of circulating mesenchymal 
precursors of a monocyte/macrophage lineage. Am J Pathol. 
2006;168:659-69.
28. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, 
Stewart DJ. Rescue of monocrotaline-induced pulmonary arte-
rial hypertension using bone marrow-derived endothelial-like 
progenitor cells: efficacy of combined cell and eNOS gene 
therapy in established disease. Circ Res. 2005;96:442-50.
29. International PPH Consortium, Lane KB, Machado RD, 
Pauciulo MW, Thomson JR, Phillips JA 3rd, et al. 
Heterozygous germline mutations in BMPR2, encoding a 
TGF-beta receptor, cause familial primary pulmonary 
hypertension. Nat Genet. 2000;26:81-4.
30. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, 
Phillips JA 3rd, et al. Mutation in the gene for bone morpho-
genetic protein receptor II as a cause of primary pulmonary 
hypertension in a large kindred. N Engl J Med. 2001;345 
:319-24.
31. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, 
Bugnet AS, et al. Polymorphism of the serotonin transporter 
gene and pulmonary hypertension in chronic obstructive pul-
monary disease. Circulation. 2003;108:1839-44.
32. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, 
Svensson EC, et al. Epigenetic attenuation of mitochondrial 
superoxide dismutase 2 in pulmonary arterial hypertension: a 
basis for excessive cell proliferation and a new therapeutic 
target. Circulation. 2010;121:2661-71.
33. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N 
Engl J Med. 2004;351:1655-65.
34. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary 
arterial hypertension. J Mol Cell Cardiol. 2008;44:14-30.
35. Chan SY, Loscalzo J. MicroRNA-210: a unique and pleio-
tropic hypoxamir. Cell Cycle. 2010;9:1072-83.
36. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. 
Differential gene up-regulation by hypoxia-inducible fac-
tor-1alpha and hypoxia-inducible factor-2alpha in HEK293T 
cells. Cancer Res. 2005;65:3299-306.
37. Maynard MA, Evans AJ, Hosomi T, Hara S, Jewett MA, Ohh 
M. Human HIF-3alpha4 is a dominant-negative regulator of 
HIF-1 and is down-regulated in renal cell carcinoma. FASEB 
J. 2005;19:1396-406.
38. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell 
Death Differ. 2008;15:621-7.
39. Adams JM, Difazio LT, Rolandelli RH, Lujan JJ, Hasko G, 
Csoka B, et al. HIF-1: a key mediator in hypoxia. Acta 
Physiol Hung. 2009;96:19-28.
40. Shimoda LA, Semenza GL. HIF and the lung: role of hypo-
xia-inducible factors in pulmonary development and disease. 
Am J Respir Crit Care Med. 2011;183:152-6.
41. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, 
et al. MicroRNA-21 integrates pathogenic signaling to con-
trol pulmonary hypertension: results of a network bio-
informatics approach. Circulation. 2012;125:1520-32.
42. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, 
Southgate M, et al. Dynamic changes in lung microRNA pro-
files during the development of pulmonary hypertension due 
to chronic hypoxia and monocrotaline. Arterioscler Thromb 
Vasc Biol. 2010;30:716-23.
43. Yang S, Banerjee S, Freitas Ad, Cui H, Xie N, Abraham E, et 
al. miR-21 regulates chronic hypoxia-induced pulmonary 
vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 
2012;302:L521-9.
44. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, 
Meloche J, et al. Role for miR-204 in human pulmonary arte-
rial hypertension. J Exp Med. 2011;208:535-48.
45. Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, 
Lehmann U, Maus UA, et al. Plexiform vasculopathy of se-
vere pulmonary arterial hypertension and microRNA 
expression. J Heart Lung Transplant. 2012;31:764-72.
46. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, 
Fischler M, et al. Interleukin-6 modulates the expression of 
the bone morphogenic protein receptor type II through a nov-
el STAT3-microRNA cluster 17/92 pathway. Circ Res. 
2009;104:1184-91.
47. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov 
B, Dahal BK, et al. Inhibition of microRNA-17 improves 
lung and heart function in experimental pulmonary 
hypertension. Am J Respir Crit Care Med. 2012;185:409-19.
48. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, 
Ulrich S, Gay RE, et al. AntagomiR directed against miR-20a 
restores functional BMPR2 signalling and prevents vascular 
remodelling in hypoxia-induced pulmonary hypertension. 
Eur Heart J. 2012 Mar 26 [Epub].
49. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, 
Lu R, et al. A role for miR-145 in pulmonary arterial hyper-
tension: evidence from mouse models and patient samples. 
Circ Res. 2012;111:290-300.
Stephen Y. Chan et al.
J Korean Soc Hypertens 2013;19(1):1-16  15
50. Guo L, Qiu Z, Wei L, Yu X, Gao X, Jiang S, et al. The 
microRNA-328 regulates hypoxic pulmonary hypertension 
by targeting at insulin growth factor 1 receptor and L-type cal-
cium channel-α1C. Hypertension. 2012;59:1006-13.
51. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA, 
et al. An endothelial apelin-FGF link mediated by miR-424 
and miR-503 is disrupted in pulmonary arterial hypertension. 
Nat Med. 2013;19:74-82.
52. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, 
Pogosova-Agadjanyan EL, et al. Circulating microRNAs as 
stable blood-based markers for cancer detection. Proc Natl 
Acad Sci U S A. 2008;105:10513-8.
53. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, 
Pulford K, et al. Detection of elevated levels of tumour-asso-
ciated microRNAs in serum of patients with diffuse large 
B-cell lymphoma. Br J Haematol. 2008;141:672-5.
54. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. 
Characterization of microRNAs in serum: a novel class of bi-
omarkers for diagnosis of cancer and other diseases. Cell Res. 
2008;18:997-1006.
55. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, 
Denecke B, et al. Delivery of microRNA-126 by apoptotic 
bodies induces CXCL12-dependent vascular protection. Sci 
Signal. 2009;2:ra81.
56. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall 
JO. Exosome-mediated transfer of mRNAs and microRNAs 
is a novel mechanism of genetic exchange between cells. Nat 
Cell Biol. 2007;9:654-9.
57. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, 
Gibson DF, et al. Argonaute2 complexes carry a population of 
circulating microRNAs independent of vesicles in human 
plasma. Proc Natl Acad Sci U S A. 2011;108:5003-8.
58. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, 
Remaley AT. MicroRNAs are transported in plasma and de-
livered to recipient cells by high-density lipoproteins. Nat 
Cell Biol. 2011;13:423-33.
59. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita 
M, et al. Increased microRNA-1 and microRNA-133a levels 
in serum of patients with cardiovascular disease indicate my-
ocardial damage. Circ Cardiovasc Genet. 2011;4:446-54.
60. Rhodes CJ, Wharton J, Boon RA, Roexe T, Tsang H, 
Wojciak-Stothard B, et al. Reduced microRNA-150 is asso-
ciated with poor survival in pulmonary arterial hypertension. 
Am J Respir Crit Care Med. 2013;187:294-302.
61. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted 
monocytic miR-150 enhances targeted endothelial cell 
migration. Mol Cell. 2010;39:133-44.
62. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van 
Eijndhoven MA, Hopmans ES, Lindenberg JL, et al. 
Functional delivery of viral miRNAs via exosomes. Proc Natl 
Acad Sci U S A. 2010;107:6328-33.
63. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, 
Gonzalez S, Sanchez-Cabo F, Gonzalez MA, et al. 
Unidirectional transfer of microRNA-loaded exosomes from 
T cells to antigen-presenting cells. Nat Commun. 2011;2:282.
64. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating 
microRNAs: biomarkers or mediators of cardiovascular dis-
eases? Arterioscler Thromb Vasc Biol. 2011;31:2383-90.
65. Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating 
microRNAs: novel biomarkers for cardiovascular diseases. J 
Mol Med (Berl). 2012;90:865-75.
66. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: 
novel biomarkers and extracellular communicators in car-
diovascular disease? Circ Res. 2012;110:483-95.
67. Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, 
Torres AG, Smith KG, et al. Efficient inhibition of miR-155 
function in vivo by peptide nucleic acids. Nucleic Acids Res. 
2010;38:4466-75.
68. Lennox KA, Behlke MA. Chemical modification and design of 
anti-miRNA oligonucleotides. Gene Ther. 2011;18:1111-20.
69. Montgomery RL, van Rooij E. Therapeutic advances in 
MicroRNA targeting. J Cardiovasc Pharmacol. 2011;57:1-7.
70. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, 
Manoharan M, et al. Silencing of microRNAs in vivo with 
‘antagomirs’. Nature. 2005;438:685-9.
71. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, 
et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 
2007;13:613-8.
72. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et 
al. MicroRNA-21 contributes to myocardial disease by stim-
ulating MAP kinase signalling in fibroblasts. Nature. 
2008;456:980-4.
73. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson 
EG, et al. Therapeutic silencing of miR-10b inhibits meta-
stasis in a mouse mammary tumor model. Nat Biotechnol. 
2010;28:341-7.
74. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, 
MicroRNA in the Diseased Pulmonary Vasculature
16  The Korean Society of Hypertension
Saltzman WM, et al. Nanoparticle-based therapy in an in vivo 
microRNA-155 (miR-155)-dependent mouse model of 
lymphoma. Proc Natl Acad Sci U S A. 2012;109:E1695-704.
75. Cheng CJ, Saltzman WM. Polymer nanoparticle-mediated 
delivery of microRNA inhibition and alternative splicing. 
Mol Pharm. 2012;9:1481-8.
